CA2689608A1 - Utilisation de la citrulline pour la prevention de l`augmentation de la carbonylation des proteines et du traitement des pathologies qui en decoulent - Google Patents

Utilisation de la citrulline pour la prevention de l`augmentation de la carbonylation des proteines et du traitement des pathologies qui en decoulent Download PDF

Info

Publication number
CA2689608A1
CA2689608A1 CA002689608A CA2689608A CA2689608A1 CA 2689608 A1 CA2689608 A1 CA 2689608A1 CA 002689608 A CA002689608 A CA 002689608A CA 2689608 A CA2689608 A CA 2689608A CA 2689608 A1 CA2689608 A1 CA 2689608A1
Authority
CA
Canada
Prior art keywords
treatment
citrulline
composition
nutrition
use according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002689608A
Other languages
English (en)
French (fr)
Inventor
Christophe Moinard
Stephane Walrand
Yves Boirie
Luc Cynober
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Assistance Publique - Hôpitaux de Paris
Institut National de la Recherche Agronomique
Université Paris Descartes
Centre Hospitalier Universitaire de Clermont-Ferrand
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2689608A1 publication Critical patent/CA2689608A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A23L33/175—Amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
    • A61K8/44—Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof
    • A61K8/442—Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof substituted by amido group(s)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/08—Anti-ageing preparations
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Dermatology (AREA)
  • Nutrition Science (AREA)
  • Obesity (AREA)
  • Food Science & Technology (AREA)
  • Diabetes (AREA)
  • Birds (AREA)
  • Polymers & Plastics (AREA)
  • Hematology (AREA)
  • Mycology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Rheumatology (AREA)
  • Psychology (AREA)
  • Gerontology & Geriatric Medicine (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Vascular Medicine (AREA)
  • Psychiatry (AREA)
  • Immunology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
CA002689608A 2007-03-22 2008-03-20 Utilisation de la citrulline pour la prevention de l`augmentation de la carbonylation des proteines et du traitement des pathologies qui en decoulent Abandoned CA2689608A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR0702090 2007-03-22
FR0702090A FR2913885B1 (fr) 2007-03-22 2007-03-22 Utilisation de la citrulline pour le traitement des pathologies liees a une augmentation de la carbonylation des proteines
PCT/FR2008/000379 WO2008135661A2 (fr) 2007-03-22 2008-03-20 Utilisation de la citrulline pour pour le traitement de pathologies liees a une augmentation de la carbonylation des protéines

Publications (1)

Publication Number Publication Date
CA2689608A1 true CA2689608A1 (fr) 2008-11-13

Family

ID=38561836

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002689608A Abandoned CA2689608A1 (fr) 2007-03-22 2008-03-20 Utilisation de la citrulline pour la prevention de l`augmentation de la carbonylation des proteines et du traitement des pathologies qui en decoulent

Country Status (8)

Country Link
US (1) US20100093863A1 (enExample)
EP (1) EP2136777A2 (enExample)
JP (1) JP2010522146A (enExample)
CN (1) CN101686919A (enExample)
CA (1) CA2689608A1 (enExample)
FR (1) FR2913885B1 (enExample)
IL (1) IL200830A0 (enExample)
WO (1) WO2008135661A2 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102600260A (zh) * 2010-12-24 2012-07-25 漆又毛 一种氨基酸和提取物组合物防治老年性痴呆的药物用途
EP2685987B1 (en) * 2011-03-18 2019-04-24 Nestec S.A. Compositions and methods useful for ameliorating age related maladies
JP2014512372A (ja) * 2011-04-18 2014-05-22 ネステク ソシエテ アノニム α−ＨＩＣＡ及びエイコサペンタエン酸を含有する栄養組成物
WO2014125376A2 (en) * 2013-02-15 2014-08-21 Mediterranean Institute For Life Sciences Protein damage in aging and age-related diseases
CN106137782A (zh) * 2015-04-22 2016-11-23 捷通国际有限公司 包含青藤碱的局部组合物及用于抑制蛋白羰基化的方法
JP7220838B2 (ja) * 2015-09-29 2023-02-13 学校法人北里研究所 経口組成物
CN105147684B (zh) * 2015-09-30 2017-12-12 暨南大学 胡椒碱在制备防治败血症药物中的应用
KR102531118B1 (ko) * 2023-01-05 2023-05-11 주식회사 마이크로엑스 패혈증의 예방, 개선 또는 치료용 조성물

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5385938B1 (en) * 1986-12-23 1997-07-15 Tristrata Inc Method of using glycolic acid for treating wrinkles
FR2691359B1 (fr) * 1992-05-20 1995-06-23 Krempf Michel Nouvelle application therapeutique du malate de 1-citrulline.
DE4341000A1 (de) * 1993-12-02 1995-06-08 Beiersdorf Ag Verwendung von L-Arginin, L-Ornithin oder L-Citrullin und topischen Zubereitungen mit diesen Stoffen
FR2766712B1 (fr) * 1997-08-01 1999-10-22 Aguettant Lab Composition de preference solution antioxydante et medicaments en faisant application
US20010056068A1 (en) * 1998-03-04 2001-12-27 Kristof Chwalisz Method of treatment and prevention of nitric oxide deficiency-related disorders with citrulline and citrulline derivatives
US9486429B2 (en) * 1999-06-01 2016-11-08 Vanderbilt University Therapeutic methods employing nitric oxide precursors
DE19929993C2 (de) * 1999-06-30 2001-07-05 Sueddeutsche Kalkstickstoff Kreatin-alpha-ketoglutarate, Verfahren zu ihrer Herstellung und ihre Verwendung
NL1014380C2 (nl) * 2000-02-14 2001-08-15 Friesland Brands Bv Darmwandversterkend voedingsmiddel.
JP3843298B2 (ja) * 2001-02-05 2006-11-08 国立大学法人 奈良先端科学技術大学院大学 シトルリンを含有する活性酸素消去剤
US20040087490A1 (en) * 2002-09-20 2004-05-06 Troup John P. Nutritional compositions
US20060063827A1 (en) * 2004-09-23 2006-03-23 Yu Ruey J Systemic administration of therapeutic amino acids and N-acetylamino acids
FR2853210B1 (fr) * 2003-04-02 2006-12-15 Neolait Sas Composition activateur de la digestion
US20060247207A1 (en) * 2003-07-01 2006-11-02 Pierzynowski Stefan G Use of alpha-ketoglutaric acid for the treatment of malnutrition or high plasma glucose condition
FR2857262B1 (fr) * 2003-07-08 2007-10-05 Biocodex Lab Utilisation de la citrulline dans le cadre de l'insuffisance intestinale
JP3878612B2 (ja) * 2004-03-01 2007-02-07 ピアス株式会社 活性酸素抑制用の組成物と、その組成物を配合する皮膚外用剤及び化粧料
FR2869539B1 (fr) * 2004-04-29 2008-08-08 Univ Paris Descartes Compositions pharmaceutiques pour la prevention et le traitement de l'atherosclerose
JP4887499B2 (ja) * 2004-04-30 2012-02-29 国立大学法人 奈良先端科学技術大学院大学 野生種スイカ抽出物を含有する活性酸素消去剤ならびに保湿剤
US20060046982A1 (en) * 2004-08-26 2006-03-02 Waugh William H Orthomolecular medical use of L-citrulline for capillary endothelial protection and adjacent cell protection in neurodegenerative disease
JP4255432B2 (ja) * 2004-10-28 2009-04-15 株式会社ファンケル 異常蛋白質除去用組成物
WO2006131054A1 (en) * 2005-06-04 2006-12-14 Zichun Li Chinese pharmaceutical ophthalmological formulations in forms of solutions, ointments and pills for antiaging recovery
JP5188181B2 (ja) * 2005-08-25 2013-04-24 協和発酵バイオ株式会社 血中アルコール濃度上昇抑制用組成物
CA2648126C (en) * 2006-04-04 2012-12-18 Nestec S.A. Treatments using citrulline
FR2907011B1 (fr) * 2006-10-17 2010-05-14 Univ Paris Descartes Utilisation de la citrulline pour le traitement des etats de denutrition

Also Published As

Publication number Publication date
FR2913885A1 (fr) 2008-09-26
WO2008135661A2 (fr) 2008-11-13
IL200830A0 (en) 2010-05-17
WO2008135661A3 (fr) 2009-01-15
US20100093863A1 (en) 2010-04-15
FR2913885B1 (fr) 2012-07-20
CN101686919A (zh) 2010-03-31
JP2010522146A (ja) 2010-07-01
EP2136777A2 (fr) 2009-12-30

Similar Documents

Publication Publication Date Title
JP4850986B2 (ja) カルノシンあるいはその誘導体および分枝アミノ酸を含む抗酸化活性を有する医薬組成物および／または栄養組成物
ES2256472T3 (es) Productos fenolicos naturales y derivados de los mismos para la proteccion frente a enfermedades neurodegenerativas.
EP2136777A2 (fr) Utilisation de la citrulline pour le traitement de pathologies liees a une augmentation de la carbonylation des proteines
EP2081564B1 (fr) Utilisation de la citrulline pour le traitement des etats de denutrition
CN115209864A (zh) 具有改良稳定性的包含燕麦蒽酰胺或其类似物的组合物
ES2232443T3 (es) Composicion que comprende una carnitina y glutationa, util para aumentar la absorcion de glutationa y producir efectos sinergicos.
EP2478899B1 (en) Composition for alleviating ultraviolet irradiation-induced damage
JP2024010082A (ja) オートファジーおよびリポファジーを調節するためのβ－ヒドロキシ－β－メチルブチレート（ＨＭＢ）の組成物および使用方法
JP6669750B2 (ja) 環状ジペプチド含有血清カルノシン分解酵素阻害用組成物
TW201039858A (en) Composition for alleviating ultraviolet radiation-induced damage
US9480668B2 (en) Blood flow promoting agent
JP6723407B2 (ja) 中枢神経作用改善用組成物、あるいは食品
US9526793B1 (en) Salts of phenylethylamines and inorganic acids and methods of use thereof
CN104619317A (zh) 用于预防或减少tewl及相关病症和疾病的包含植物酚类的组合物
Sa-nguanpong et al. Protective effects of Sacha inchi meal protein hydrolysate against oxidative stress and endothelial dysfunction via MDA suppression and SOD activation in L-NAME-induced hypertensive rats
WO2007095117A2 (en) Method for improving the oral administration of alpha-lipoic acid
WO2015002279A1 (ja) グルタチオン生成促進用組成物
EP3902518A1 (fr) Extrait de chlamydomonas acidophila, son procede de preparation et les compositions cosmetiques, et dermatologiques le comprenant
CN111565580A (zh) 用于抑制活性氧产生的组合物
WO2002100393A1 (fr) Compositions destinees a ameliorer les troubles de manque d'attention/d'hyperactivite
EP4298924A1 (en) Composition, for preventing, relieving, or treating disease caused by nitration of protein, containing peptide having tyrosine located at terminal as active ingredient
JP2008260700A (ja) 脂肪蓄積および脂肪細胞分化を抑制するための組成物
CN110621304A (zh) 活性成分的组合、包含该组合的组合物及其在治疗肌肉减少症中的用途
Calabrese et al. Increased formation of short-chain organic acids after chronic ethanol administration and its interaction with the carnitine pool in rat
WO2025083752A1 (ja) 低用量グルタチオンの肌の明度向上剤としての使用

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued

Effective date: 20171002